Clinical Trial Detail

NCT ID NCT02289209
Title Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dan Zandberg
Indications

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma

hypopharynx cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.